Which drugs does patent 5,905,082 protect, and when does it expire?
Patent 5,905,082 protects EPIVIR, COMBIVIR, EPIVIR-HBV, EPZICOM, TRIUMEQ, and TRIZIVIR, and is included in seven NDAs. There have been zero Paragraph IV challenges on Triumeq, Trizivir, Epivir-HBV, Epivir, Epzicom, and Combivir.
Protection for EPIVIR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty patent family members in twenty-eight countries.